Published in Antimicrob Agents Chemother on April 01, 1998
Quinolone-mediated bacterial death. Antimicrob Agents Chemother (2007) 2.94
Effect of fluoroquinolone concentration on selection of resistant mutants of Mycobacterium bovis BCG and Staphylococcus aureus. Antimicrob Agents Chemother (1999) 2.75
Fluoroquinolone action against mycobacteria: effects of C-8 substituents on growth, survival, and resistance. Antimicrob Agents Chemother (1998) 2.35
Gatifloxacin activity against quinolone-resistant gyrase: allele-specific enhancement of bacteriostatic and bactericidal activities by the C-8-methoxy group. Antimicrob Agents Chemother (1999) 2.16
Mutant prevention concentration as a measure of antibiotic potency: studies with clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother (2000) 1.87
Mechanisms and frequency of resistance to premafloxacin in Staphylococcus aureus: novel mutations suggest novel drug-target interactions. Antimicrob Agents Chemother (2000) 1.66
Fluoroquinolone action against clinical isolates of Mycobacterium tuberculosis: effects of a C-8 methoxyl group on survival in liquid media and in human macrophages. Antimicrob Agents Chemother (1999) 1.56
Selection of Streptococcus pneumoniae mutants having reduced susceptibility to moxifloxacin and levofloxacin. Antimicrob Agents Chemother (2002) 1.46
Dual targeting of DNA gyrase and topoisomerase IV: target interactions of garenoxacin (BMS-284756, T-3811ME), a new desfluoroquinolone. Antimicrob Agents Chemother (2002) 1.34
Selective targeting of topoisomerase IV and DNA gyrase in Staphylococcus aureus: different patterns of quinolone-induced inhibition of DNA synthesis. Antimicrob Agents Chemother (2000) 1.32
Activity of and resistance to moxifloxacin in Staphylococcus aureus. Antimicrob Agents Chemother (2003) 1.30
Enhancement of fluoroquinolone activity by C-8 halogen and methoxy moieties: action against a gyrase resistance mutant of Mycobacterium smegmatis and a gyrase-topoisomerase IV double mutant of Staphylococcus aureus. Antimicrob Agents Chemother (2001) 1.20
Mutant prevention concentration of garenoxacin (BMS-284756) for ciprofloxacin-susceptible or -resistant Staphylococcus aureus. Antimicrob Agents Chemother (2003) 1.19
Moxifloxacin lethality against Mycobacterium tuberculosis in the presence and absence of chloramphenicol. Antimicrob Agents Chemother (2006) 1.18
Mechanisms and frequency of resistance to gatifloxacin in comparison to AM-1121 and ciprofloxacin in Staphylococcus aureus. Antimicrob Agents Chemother (2001) 1.09
Contributions of the 8-methoxy group of gatifloxacin to resistance selectivity, target preference, and antibacterial activity against Streptococcus pneumoniae. Antimicrob Agents Chemother (2001) 1.08
Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model. Antimicrob Agents Chemother (2003) 1.03
Fluoroquinolone and quinazolinedione activities against wild-type and gyrase mutant strains of Mycobacterium smegmatis. Antimicrob Agents Chemother (2011) 0.97
In vitro activity of fluoroquinolones against clinical isolates of Nocardia identified by partial 16S rRNA sequencing. Eur J Clin Microbiol Infect Dis (2007) 0.94
Comparative mutant prevention concentrations of pradofloxacin and other veterinary fluoroquinolones indicate differing potentials in preventing selection of resistance. Antimicrob Agents Chemother (2005) 0.89
Alterations in DNA gyrase and topoisomerase IV in resistant mutants of Clostridium perfringens found after in vitro treatment with fluoroquinolones. Antimicrob Agents Chemother (2005) 0.87
Effect of N-1/c-8 ring fusion and C-7 ring structure on fluoroquinolone lethality. Antimicrob Agents Chemother (2010) 0.85
Propensity of fluoroquinolones with different moieties at position 8 to cause resistance development in clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother (2001) 0.81
Contribution of the 8-methoxy group to the activity of gatifloxacin against type II topoisomerases of Streptococcus pneumoniae. Antimicrob Agents Chemother (2003) 0.79
Contribution of the C-8-methoxy group of gatifloxacin to inhibition of type II topoisomerases of Staphylococcus aureus. Antimicrob Agents Chemother (2002) 0.75
DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev (1997) 9.69
Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones. Mol Microbiol (1994) 7.89
Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae. Antimicrob Agents Chemother (1996) 7.10
Studies on plasmid replication. I. Plasmid incompatibility and establishment in Staphylococcus aureus. J Mol Biol (1972) 5.84
Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphylococcus aureus. Antimicrob Agents Chemother (1995) 5.64
Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus. Antimicrob Agents Chemother (1996) 4.42
Mechanism of action of nalidixic acid on Escherichia coli. 3. Conditions required for lethality. J Bacteriol (1966) 4.08
DNA gyrase and topoisomerase IV on the bacterial chromosome: quinolone-induced DNA cleavage. J Mol Biol (1996) 3.08
DNA topoisomerase targets of the fluoroquinolones: a strategy for avoiding bacterial resistance. Proc Natl Acad Sci U S A (1997) 2.99
Nonadaptive mutations occur on the F' episome during adaptive mutation conditions in Escherichia coli. J Bacteriol (1997) 2.46
Comparative in-vitro activities of the new quinolone, Bay y 3118, and ciprofloxacin, sparfloxacin, tosufloxacin, CI-960 and CI-990. J Antimicrob Chemother (1993) 2.29
In vitro antibacterial activity of Q-35, a new fluoroquinolone. Antimicrob Agents Chemother (1992) 1.91
Contribution of the C-8 substituent of DU-6859a, a new potent fluoroquinolone, to its activity against DNA gyrase mutants of Pseudomonas aeruginosa. Antimicrob Agents Chemother (1995) 1.84
The synthesis, structure-activity, and structure-side effect relationships of a series of 8-alkoxy- and 5-amino-8-alkoxyquinolone antibacterial agents. J Med Chem (1995) 1.49
Improved bactericidal activity of Q-35 against quinolone-resistant staphylococci. Antimicrob Agents Chemother (1995) 1.44
In vitro and in vivo activities of clinafloxacin, CI-990 (PD 131112), and PD 138312 versus enterococci. Antimicrob Agents Chemother (1995) 1.38
Protein- and RNA-synthesis independent bactericidal activity of ciprofloxacin that involves the A subunit of DNA gyrase. J Med Microbiol (1991) 1.23
Antimycobacterial quinolones: a comparative analysis of structure-activity and structure-cytotoxicity relationships. Res Microbiol (1996) 1.05
Antibacterial activity and pharmacokinetics of four new 7-azetidinyl fluoroquinolones. Antimicrob Agents Chemother (1996) 0.90
Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. Proc Natl Acad Sci U S A (1998) 39.20
Tetrahymena histone acetyltransferase A: a homolog to yeast Gcn5p linking histone acetylation to gene activation. Cell (1996) 9.86
Histonelike proteins of bacteria. Microbiol Rev (1987) 8.65
Haplotype variation and linkage disequilibrium in 313 human genes. Science (2001) 8.52
Recombination within natural populations of pathogenic bacteria: short-term empirical estimates and long-term phylogenetic consequences. Proc Natl Acad Sci U S A (2001) 7.90
Nomenclature of major antimicrobial-resistant clones of Streptococcus pneumoniae defined by the pneumococcal molecular epidemiology network. J Clin Microbiol (2001) 6.66
Phosphorylation of the retinoblastoma gene product is modulated during the cell cycle and cellular differentiation. Cell (1989) 6.46
Successful establishment of Wolbachia in Aedes populations to suppress dengue transmission. Nature (2011) 6.36
Current methods in medical image segmentation. Annu Rev Biomed Eng (2000) 6.24
Steroid receptor coactivator-1 is a histone acetyltransferase. Nature (1997) 6.15
Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene (2006) 5.86
Horizontal transfer of multiple penicillin-binding protein genes, and capsular biosynthetic genes, in natural populations of Streptococcus pneumoniae. Mol Microbiol (1991) 5.45
Geometric and electronic structure/function correlations in non-heme iron enzymes. Chem Rev (2000) 5.44
The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature (1999) 5.33
Biology of bacterial deoxyribonucleic acid topoisomerases. Microbiol Rev (1984) 5.10
American College of Rheumatology classification criteria for Sjögren's syndrome: a data-driven, expert consensus approach in the Sjögren's International Collaborative Clinical Alliance cohort. Arthritis Care Res (Hoboken) (2012) 4.82
The wMel Wolbachia strain blocks dengue and invades caged Aedes aegypti populations. Nature (2011) 4.75
Reversible tyrosine phosphorylation of cdc2: dephosphorylation accompanies activation during entry into mitosis. Cell (1989) 4.68
Escherichia coli DNA topoisomerase I mutants: increased supercoiling is corrected by mutations near gyrase genes. Cell (1982) 4.62
Histone acetyltransferase activity of yeast Gcn5p is required for the activation of target genes in vivo. Genes Dev (1998) 4.23
Infectivity, transmission, and pathology of human-isolated H7N9 influenza virus in ferrets and pigs. Science (2013) 4.17
Identification of mutations in the COL4A5 collagen gene in Alport syndrome. Science (1990) 4.15
Phosphotyrosine-containing proteins are concentrated in focal adhesions and intercellular junctions in normal cells. Proc Natl Acad Sci U S A (1985) 3.76
Evaluation of PCR-generated chimeras, mutations, and heteroduplexes with 16S rRNA gene-based cloning. Appl Environ Microbiol (2001) 3.76
The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study. Leukemia (2008) 3.69
Differential roles of p300 and PCAF acetyltransferases in muscle differentiation. Mol Cell (1997) 3.54
Role of interspecies transfer of chromosomal genes in the evolution of penicillin resistance in pathogenic and commensal Neisseria species. J Mol Evol (1992) 3.44
DNA gyrase on the bacterial chromosome: DNA cleavage induced by oxolinic acid. J Mol Biol (1979) 3.43
Three distinct signalling responses by murine fibroblasts to genotoxic stress. Nature (1996) 3.37
Development and evaluation of functional gene arrays for detection of selected genes in the environment. Appl Environ Microbiol (2001) 3.36
Acetylation of MyoD directed by PCAF is necessary for the execution of the muscle program. Mol Cell (1999) 3.30
Design of organic molecules with large two-photon absorption cross sections. Science (1998) 3.27
Creating a pandemic of prediabetes: the proposed new diagnostic criteria for impaired fasting glycaemia. Diabetologia (2004) 3.26
CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci U S A (1997) 3.25
Homocysteine-induced endoplasmic reticulum stress causes dysregulation of the cholesterol and triglyceride biosynthetic pathways. J Clin Invest (2001) 3.24
DNA supercoiling and prokaryotic transcription. Cell (1989) 3.21
ESA1 is a histone acetyltransferase that is essential for growth in yeast. Proc Natl Acad Sci U S A (1998) 3.19
Isolation, characterization, and distribution of denitrifying toluene degraders from a variety of habitats. Appl Environ Microbiol (1994) 3.09
DNA gyrase and topoisomerase IV on the bacterial chromosome: quinolone-induced DNA cleavage. J Mol Biol (1996) 3.08
Perinatal lethality with kidney and pancreas defects in mice with a targetted Pkd1 mutation. Nat Genet (1997) 3.06
DNA topoisomerase targets of the fluoroquinolones: a strategy for avoiding bacterial resistance. Proc Natl Acad Sci U S A (1997) 2.99
Ataxia telangiectasia mutant protein activates c-Abl tyrosine kinase in response to ionizing radiation. Nature (1997) 2.98
Risk factors for surgical site infection after elective resection of the colon and rectum: a single-center prospective study of 2,809 consecutive patients. Ann Surg (2001) 2.96
p38 and extracellular signal-regulated kinases regulate the myogenic program at multiple steps. Mol Cell Biol (2000) 2.96
Superhelical Escherichia coli DNA: relaxation by coumermycin. J Mol Biol (1978) 2.95
Regulation of histone acetyltransferases p300 and PCAF by the bHLH protein twist and adenoviral oncoprotein E1A. Cell (1999) 2.90
Retinoblastoma cancer suppressor gene product is a substrate of the cell cycle regulator cdc2 kinase. EMBO J (1991) 2.84
Search for a resonance decaying into WZ boson pairs in pp collisions. Phys Rev Lett (2010) 2.83
Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies. Clin Infect Dis (2001) 2.81
A C-terminal protein-binding domain in the retinoblastoma protein regulates nuclear c-Abl tyrosine kinase in the cell cycle. Cell (1993) 2.80
Effect of fluoroquinolone concentration on selection of resistant mutants of Mycobacterium bovis BCG and Staphylococcus aureus. Antimicrob Agents Chemother (1999) 2.75
Genome-wide expression profiling of human blood reveals biomarkers for Huntington's disease. Proc Natl Acad Sci U S A (2005) 2.75
cisRED: a database system for genome-scale computational discovery of regulatory elements. Nucleic Acids Res (2006) 2.75
Isolation of antibodies for phosphotyrosine by immunization with a v-abl oncogene-encoded protein. Mol Cell Biol (1985) 2.74
Nuclear-cytoplasmic shuttling of C-ABL tyrosine kinase. Proc Natl Acad Sci U S A (1998) 2.73
Nitrite reductase genes (nirK and nirS) as functional markers to investigate diversity of denitrifying bacteria in pacific northwest marine sediment communities. Appl Environ Microbiol (2000) 2.72
Class I histone deacetylases sequentially interact with MyoD and pRb during skeletal myogenesis. Mol Cell (2001) 2.69
Endocytosis of activated TrkA: evidence that nerve growth factor induces formation of signaling endosomes. J Neurosci (1996) 2.65
Overexpression of innate immune response genes in a model of recessive polycystic kidney disease. Kidney Int (2007) 2.64
Association of Nef with the human immunodeficiency virus type 1 core. J Virol (1999) 2.62
Bacterial chromosome segregation: evidence for DNA gyrase involvement in decatenation. Cell (1984) 2.58
The p53/p63/p73 family of transcription factors: overlapping and distinct functions. J Cell Sci (2000) 2.55
Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase. Nat Med (2001) 2.51
Protein array autoantibody profiles for insights into systemic lupus erythematosus and incomplete lupus syndromes. Clin Exp Immunol (2007) 2.51
Structure of Tetrahymena GCN5 bound to coenzyme A and a histone H3 peptide. Nature (1999) 2.50
Topoisomerase I mutants: the gene on pBR322 that encodes resistance to tetracycline affects plasmid DNA supercoiling. Proc Natl Acad Sci U S A (1986) 2.45
Regulation of bacterial DNA supercoiling: plasmid linking numbers vary with growth temperature. Proc Natl Acad Sci U S A (1984) 2.41
Simultaneous recovery of RNA and DNA from soils and sediments. Appl Environ Microbiol (2001) 2.38
Intermediate homocysteinemia: a thermolabile variant of methylenetetrahydrofolate reductase. Am J Hum Genet (1988) 2.35
Fluoroquinolone action against mycobacteria: effects of C-8 substituents on growth, survival, and resistance. Antimicrob Agents Chemother (1998) 2.35
Selection of antibiotic-resistant bacterial mutants: allelic diversity among fluoroquinolone-resistant mutations. J Infect Dis (2000) 2.35
The mouse c-abl locus: molecular cloning and characterization. Cell (1984) 2.33
Two-Photon Fluorescence Excitation Cross Sections of Biomolecular Probes from 690 to 960 nm. Appl Opt (1998) 2.31
FGF inactivates myogenic helix-loop-helix proteins through phosphorylation of a conserved protein kinase C site in their DNA-binding domains. Cell (1992) 2.28
Dual mechanisms for the inhibition of E2F binding to RB by cyclin-dependent kinase-mediated RB phosphorylation. Mol Cell Biol (1997) 2.25
Papillomavirus capsid binding and uptake by cells from different tissues and species. J Virol (1995) 2.24
Differential regulation of retinoblastoma protein function by specific Cdk phosphorylation sites. J Biol Chem (1996) 2.23
Fluoroquinolone resistance associated with specific gyrase mutations in clinical isolates of multidrug-resistant Mycobacterium tuberculosis. J Infect Dis (1996) 2.22
Cloning and functional analysis of cDNAs with open reading frames for 300 previously undefined genes expressed in CD34+ hematopoietic stem/progenitor cells. Genome Res (2000) 2.21
Induction of terminal differentiation by constitutive activation of p38 MAP kinase in human rhabdomyosarcoma cells. Genes Dev (2000) 2.21
Randomised clinical trial: herbal extract HMPL-004 in active ulcerative colitis - a double-blind comparison with sustained release mesalazine. Aliment Pharmacol Ther (2010) 2.20
Integrin regulation of c-Abl tyrosine kinase activity and cytoplasmic-nuclear transport. Proc Natl Acad Sci U S A (1996) 2.19
Development of a real-time PCR method for Firmicutes and Bacteroidetes in faeces and its application to quantify intestinal population of obese and lean pigs. Lett Appl Microbiol (2008) 2.19
A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins. Mol Cell Biol (1993) 2.18
Tyrosine phosphorylation of mammalian RNA polymerase II carboxyl-terminal domain. Proc Natl Acad Sci U S A (1993) 2.17
Polycystin-L is a calcium-regulated cation channel permeable to calcium ions. Nature (1999) 2.17
Gatifloxacin activity against quinolone-resistant gyrase: allele-specific enhancement of bacteriostatic and bactericidal activities by the C-8-methoxy group. Antimicrob Agents Chemother (1999) 2.16
Inhibitors of HIV nucleocapsid protein zinc fingers as candidates for the treatment of AIDS. Science (1995) 2.16
PEGylated PLGA nanoparticles as protein carriers: synthesis, preparation and biodistribution in rats. J Control Release (2001) 2.15
Deletion of an N-terminal regulatory domain of the c-abl tyrosine kinase activates its oncogenic potential. EMBO J (1989) 2.13
The central melanocortin system can directly regulate serum insulin levels. Endocrinology (2000) 2.09
Comparison of Pkd1-targeted mutants reveals that loss of polycystin-1 causes cystogenesis and bone defects. Hum Mol Genet (2001) 2.09
RB-dependent S-phase response to DNA damage. Mol Cell Biol (2000) 2.08